A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

ABSTRACT: This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A*0201 positive patients with WT1 positive recurrent/metastatic solid tumors who have failed conventional therapies.

DISEASE(S): Ovarian Cancer,Neoplasm Metastasis,Colorectal Cancer,Gastric Cancer,Pancreatic Cancer

PROVIDER: 2726735 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR